Table 1A.
Name of the Compound | Drug used for the purpose | References | Therapeutic targets of SARS-CoV-2 | Docking Score | MMGBSA Score |
---|---|---|---|---|---|
Anti-inflammatory | |||||
Rutin Hydrate | Anti-inflammatory, Antioxidant, Inhibitor of platelet aggregation, reduced heart risks |
(Ojha et al., 2016) | RDRP | −11.37 | −65.34 |
Helicase | −9.57 | −87.32 | |||
Spike Protein | −9.83 | −71.83 | |||
PLprotein | −11.44 | −72.29 | |||
3CLpro | −12.66 | −101.17 | |||
EndoRNAse | −10.13 | −92.21 | |||
Methyltransferase | −9.07 | −70.4 | |||
Nucleocapsid | −13.76 | −100.03 | |||
Silymarin | Anti-inflammatory Hepatoprotective, antioxidant, anticancer, and cardioprotective activities | (Baliga et al., 2014) | Exoribonucleases | −6.14 | −77.75 |
Spike Protein | −5.88 | −58.7 | |||
Spike protein complex with ACE2 | −5.61 | −64.41 | |||
RDRP | −5.9 | −41.01 | |||
EndoRNAse | −7.08 | −62.4 | |||
Helicase | −7.82 | −113.86 | |||
Nucleocapsid | −10.02 | −60.65 | |||
Quercetin | Antioxidant and anti-aging agent and anti-carcinogenic | (Li et al., 2016) | 3CLpro | −9.07 | −70.4 |
Helicase | −13.76 | −100.03 | |||
Spike Protein | −12.66 | −101.17 | |||
Spike protein complex with ACE2 | −9.57 | −87.32 | |||
RDRP | −5.35 | −48.75 | |||
EndoRNAse | −6.7 | −50.99 | |||
Exoribonucleases | −6.55 | −40.73 | |||
Mitoxantrone 2Hcl | Antineoplastic agent used to treat multiple sclerosis, Immunosuppressant | (Fox, 2004) | Helicase | −8.35 | −98.48 |
Spike Protein | −6.15 | −48.46 | |||
Spike protein complex with ACE2 | −8.11 | −68.28 | |||
RDRP | −8.13 | −77.04 | |||
EndoRNAse | −6.66 | −71.5 | |||
Methyltransferase | −6.69 | −65.44 | |||
Nucleocapsid | −9.5 | −63.22 | |||
Luteolin | Anti-inflammatory and Neuroprotective agent | (Nabavi et al., 2015) | Helicase | −4.52 | −73.99 |
3CLpro | −7.50 | −61.63 | |||
Spike protein complex with ACE2 | −5.84 | −46.31 | |||
PLprotein | −4.80 | −33.54 | |||
EndoRNAse | −7.18 | −61.06 | |||
Methyltransferase | −3.87 | −42.55 | |||
Aloin | Anti-inflammatory used to treat acute Influenza. Antiarrhythmic, Anti-carcinogenic | (Huang et al., 2019) | Spike Protein | −7.52 | −46.36 |
Spike protein complex with ACE2 | −6.19 | −52.55 | |||
RDRP | −7.47 | −43.78 | |||
EndoRNAse | −10.25 | −50.69 | |||
Methyltransferase | −7.13 | −27.61 | |||
Nucleocapsid | −8.24 | −50.03 | |||
Morin Hydrate | Anti-inflammatory, antiproliferative | (Choudhury et al., 2017) | 3CLpro | −6.92 | −58.7 |
Helicase | −4.95 | −75.72 | |||
Spike Protein | −3.13 | −37.39 | |||
Spike protein complex with ACE2 | −6.15 | −45.3 | |||
EndoRNAse | −6.32 | −44.79 | |||
Exoribonucleases | −6.56 | −52 | |||
Kaempferol | Anti-colorectal cancer (CRC) drug | (Riahi-Chebbi et al., 2019) | 3CLpro | −7.48 | −43.88 |
Spike Protein | −3.58 | −40.92 | |||
Spike protein complex with ACE2 | −5.49 | −43.44 | |||
Exoribonucleases | −5.23 | −41.17 | |||
Nucleocapsid | −6.1 | −34.75 | |||
Madecassoside | Anti-inflammatory, wound healing, and antioxidant | (Li et al., 2007) | Helicase | −9.62 | −131.31 |
RDRP | −10.05 | −36.38 | |||
Antibiotics | |||||
Amikacin Hydrate | Antibiotic | (Torres et al., 2018) | Helicase | −7.71 | −53.43 |
Spike Protein | −9.28 | −66.72 | |||
Spike protein complex with ACE2 | −13.08 | −71.28 | |||
EndoRNAse | −10.37 | −82.08 | |||
Methyltransferase | −7.73 | −71.19 | |||
Exoribonucleases | −9.61 | −88.19 | |||
Geneticin | Aminoglycoside antibiotic | (Zufferey et al., 2012) | Methyltransferase | −5.37 | −59.72 |
Spike protein complex with ACE2 | −7.19 | −63.84 | |||
RDRP | −10.25 | −61.95 | |||
EndoRNAse | −6.91 | −76.69 | |||
Spike Protein | −4.4 | −44.03 | |||
Netilmicin Sulfate | Antibiotic | (Craig et al., 1983) | Spike Protein | −2.96 | −50.37 |
Spike protein complex with ACE2 | −9.85 | −86.57 | |||
Methyltransferase | −6.86 | −71.81 | |||
Hygromycin B | Antibiotic (kills bacteria, fungi and higher eukaryotic cells) | (Kirst & Allen, 2007) | EndoRNAse | −8.12 | −94.09 |
Spike protein complex with ACE2 | −10.97 | −68.83 | |||
RDRP | −9.98 | −63.5 | |||
Spike Protein | −3.71 | −37.87 | |||
Nucleocapsid | −10.1 | −55.66 | |||
Antidiabetics | |||||
Acarbose | Antidiabetic (Type 2 Diabetes Mellitus) | (Chiasson et al., 2002) | Spike protein complex with ACE2 | −11.07 | −74.88 |
PLprotein | −9.74 | −55.2 | |||
RDRP | −10.99 | −60.78 | |||
EndoRNAse | −10.67 | −73.16 | |||
Exoribonucleases | −10.67 | −104.11 | |||
Nucleocapsid | −14.58 | −81.08 | |||
Apigenin | Anti-diabetes, amnesia and Alzheimer's disease, depression and insomnia, Anti-cancer, etc. | (Salehi et al., 2019) | 3CLpro | −6.86 | −49.99 |
Spike protein complex with ACE2 | −4.38 | −34.62 | |||
Methyltransferase | −3.98 | −31.76 | |||
Exoribonucleases | −4.07 | −48.02 | |||
Nucleocapsid | −5.37 | −40.02 | |||
Hesperidin | Antihyperlipidemic, Cardioprotective, Antihypertensive, Antidiabetic a | (Zanwar et al., 2014) | 3CLpro | −10.68 | −91.32 |
Helicase | −7.71 | −67.17 | |||
PL protein | −8.47 | −52.6 | |||
Nucleocapsid | −11.68 | −84.31 | |||
Neohesperidin | Diabetes Mellitus | (Wu et al., 2017) | Spike Protein | −6.83 | −65.7 |
RDRP | −9.95 | −87.01 | |||
EndoRNAse | −8.69 | −70.83 | |||
Nucleocapsid | −10.84 | −75.55 | |||
Troxerutin | Antidiabetic, Chronic Venous Insufficiency | (Zhang et al., 2013) | RDRP | −10.01 | −72.04 |
EndoRNAse | −10.31 | −88.41 | |||
Exoribonucleases | −10.75 | −71 | |||
Nucleocapsid | −13.0 | −91.87 | |||
Notoginsenoside R1 | Diabetic nephropathy, cardiovascular disease, cerebral vascular disease, and liver dysfunction | (Zhang et al., 2018) | RDRP | −9.73 | −56.44 |
EndoRNAse | −11.27 | −93.95 | |||
Cardiovascular Disease | |||||
Salvianolic Acid B | Anti-diabetic, Angina pectoris, and other heart diseases, anti-inflammatory, antioxidant, hepatoprotective, neuroprotective, antidepressant | (Ma et al., 2019; Zhuang et al., 2012) | Helicase | −6.6 | −119.88 |
RDRP | −8.83 | −61.9 | |||
EndoRNAse | −10.08 | −78.14 | |||
Nucleocapsid | −11.24 | −86.25 |